Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.96 |
| ▸ | PPARG | P37231 | 8/20 | 0.96 |
| ▸ | F7 | P08709 | 7/20 | 0.96 |
| ▸ | F3 | P13726 | 7/20 | 0.96 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.96 |
| ▸ | PPARD | Q03181 | 6/20 | 0.96 |
| ▸ | PPARA | Q07869 | 6/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.96 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.96 |
| ▸ | MAPT | P10636 | 4/20 | 0.96 |
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606016 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL7750567 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL452559 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL4452324 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL10444556 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL7755119 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL14119798 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL7750573 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL15994740 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL29226 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694699-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VitaKey Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4678626-A1 | LONG-CHAIN ALKENYLOXY-SUBSTITUTED BENZOYL DERIVATIVE AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME | Spera Pharma, Inc. (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | claimed |
| US-20250109503-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | CHAMPIONX LLC (US) | 2025-04-03 | — | — | US | claimed |
| WO-2025071908-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | CHAMPIONX LLC (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250099553-A1 | COMPOSITION AND METHODS FOR MODULATION OF ELOVL2 | YOUHEALTH BIOTECH, LIMITED (KY) | 2025-03-27 | — | — | US | claimed |
| US-20240383850-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-21 | — | — | US | claimed |
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-14 | — | — | US | claimed |
| WO-2024216228-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VITAKEY INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4323498-A2 | CELL-CULTURED FOOD PRODUCTS AND RELATED CELLS, COMPOSITIONS, METHODS AND SYSTEMS | Bluenalu, Inc. (US) | 2024-02-21 | — | — | EP | claimed |
| JP-2010508259-A | — | — | 2010-03-18 | — | — | JP | claimed |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-02-11 | — | — | US | claimed |
| EP-2094640-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). | Pronova BioPharma Norge AS (NO) | 2009-09-02 | — | — | EP | claimed |
| US-20080182959-A1 | Novel Temperature and pH Sensitive Copolymers | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2008-07-31 | — | — | US | claimed |
| WO-2008053340-A1 | A COMBINATION PRODUCT COMPRISING AT LEAST ONE LIPID SUBSTITUTED IN THE ALPHA POSITION AND AT LEAST ONE HYPOGLYCEMIC AGENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2008-05-08 | — | — | WO | claimed |
| WO-2008053331-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). | PRONOVA BIOPHARMA NORGE A/S (SE) | 2008-05-08 | — | — | WO | claimed |
| US-7316816-B2 | Temperature and pH sensitive copolymers | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2008-01-08 | — | — | US | claimed |
| EP-1765894-A1 | NOVEL TEMPERATURE AND PH SENSITIVE COPOLYMERS | Agency for Science, Technology and Research (SG) | 2007-03-28 | — | — | EP | claimed |
| WO-2005121196-A1 | NOVEL TEMPERATURE AND PH SENSITIVE COPOLYMERS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2005-12-22 | — | — | WO | claimed |
| US-20050277739-A1 | Amphiphilic terpolymer having pH-sensitive hydrophobic units derived from a polyunsaturated fatty acid (9,12-Octadecadienoic Acid), hydrophilic units with polar groups (acrylic acid), and temperature-sensitive units (acryloylpiperidine); lower critical solution temperature decreases as pH decreases | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2005-12-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | ALDH1A1 1436/4885PPARG 1207/4885F7 3588/4885 |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PPARG, PPARA, FFAR3 | ALDH1A1 1088/4885PPARG 1/4885F7 2774/4885 |
| US-20250109503-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | FASN, FFAR1, IGF1R | ALDH1A1 887/4885PPARG 611/4885F7 881/4885 |
| US-20240383850-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | ALDH1A1 1321/4885PPARG 1606/4885F7 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.